Induction of Zeb1 KO in LSC mouse models of MLL-AF9– and Meis1a/Hoxa9-driven AML accelerated disease progression, implying that Zeb1 acts as a tumor suppressor in AML LSCs. Here, KMT2A is linked to acute myeloid leukemia.